Shopping Cart
- Remove All
- Your shopping cart is currently empty
ATM Inhibitor-1 is a highly potent, selective, and orally active ATM inhibitor (IC50: 0.7 nM) with anti-tumor activity. It exhibits weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM), and PI3Kδ (IC50, 0.73 μM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,420 | 10-14 weeks | |
50 mg | $3,180 | 10-14 weeks | |
100 mg | $4,300 | 10-14 weeks |
Description | ATM Inhibitor-1 is a highly potent, selective, and orally active ATM inhibitor (IC50: 0.7 nM) with anti-tumor activity. It exhibits weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM), and PI3Kδ (IC50, 0.73 μM). |
Targets&IC50 | PI3Kγ:3 μM, mTOR:21 μM, PI3Kα:3.8 μM, DNA-PK:2.8 μM, PI3Kβ:10.3 μM, PI3Kδ:0.73 μM, ATM:0.7 nM, ATM:2.8 nM (Cellular assay) |
In vitro | In cellular assays, ATM Inhibitor-1 (Compound 21) exhibits IC50s of 2.8 nM, >30 μM and >19 μM for ATM, ATR/PI3Kα and PI3Kβ/mTOR, respectively. |
In vivo | ATM Inhibitor-1 (50 mg/kg p.o. once daily for 3 days every week starting 24 h post-irinotecan dosing, 21 days) in combination with 50 mg/kg irinotecan significantly reduces tumor growth in SW620 mice model. |
Molecular Weight | 492.61 |
Formula | C27H36N6O3 |
Cas No. | 2135639-94-8 |
Relative Density. | 1.190 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.